×
About 11,303 results

ALLMedicine™ Hemophilia Center

Research & Reviews  3,198 results

An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B
https://clinicaltrials.gov/ct2/show/NCT02554773

Aug 5th, 2022 - It is anticipated that patients in this study will receive treatment with open label fitusiran for approximately 7 years or until fitusiran becomes commercially available, whichever occurs first.

Posture Analysis for Patients With Haemophilia
https://clinicaltrials.gov/ct2/show/NCT05173129

Aug 5th, 2022 - Hemophilia A and B are inherited disorders characterized by deficient or missing coagulation factors VIII or IX, respectively, of which the main long-term clinical manifestation is joint damage. Patients with haemophilia (PwH) are susceptible to c...

The Correlation Between the HEAD-US-C Score and HJHS in Hemophilic Arthropathy of the K...
https://doi.org/10.1002/jum.16072
Journal of Ultrasound in Medicine : Official Journal of T... Fang Y, Guo Y et. al.

Aug 4th, 2022 - We aimed to discuss the correlation between the Hemophilia Early Detection Ultrasound in China (HEAD-US-C) score and the Hemophilia Joint Health Score version 2.1 (HJHS 2.1) of the knee joint in patients with hemophilia. We included 70 male patien...

The effects of close kinetic chain exercises on proprioception and physical activity le...
https://doi.org/10.1111/hae.14645
Haemophilia : the Official Journal of the World Federatio... Gönen T, Yakut Y et. al.

Aug 4th, 2022 - Knee joint proprioception is affected, and lower extremity functioning declines over time in patients with hemophilia A. To investigate the effects of a structured exercise programme consisting of the close kinetic chain (CKC) exercises on proprio...

Percutaneous Coronary Intervention for Acute Coronary Syndrome in a 44-Year-Old Man Wit...
https://doi.org/10.14503/THIJ-20-7436
Texas Heart Institute Journal; Alhaddad Z, Al Khouri ZA et. al.

Aug 4th, 2022 - Percutaneous Coronary Intervention for Acute Coronary Syndrome in a 44-Year-Old Man With Hemophilia A.|2022|Alhaddad Z,Al Khouri ZA,Alhaddad IA,|

see more →

Guidelines  6 results

WFH Guidelines for the Management of Hemophilia, 3rd edition.
https://doi.org/10.1111/hae.14046
Haemophilia : the Official Journal of the World Federatio... Srivastava A, Santagostino E et. al.

Aug 4th, 2020 - WFH Guidelines for the Management of Hemophilia, 3rd edition.|2020|Srivastava A,Santagostino E,Dougall A,Kitchen S,Sutherland M,|therapy,

Minimal dataset for post-registration surveillance of new drugs in hemophilia: communic...
https://doi.org/10.1111/jth.13762
Journal of Thrombosis and Haemostasis : JTH; Peyvandi F, Makris M et. al.

Aug 3rd, 2017 - Minimal dataset for post-registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH.|2017|Peyvandi F,Makris M,Collins P,Lillicrap D,Pipe SW,|adverse effects,therapeutic use,standards,blood,diagnosis,drug therapy,s...

Proposal for standardized preanalytical and analytical conditions for measuring thrombi...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680042
Journal of Thrombosis and Haemostasis : JTH; Dargaud Y, Wolberg AS et. al.

Jun 29th, 2017 - Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH.|2017|Dargaud Y,Wolberg AS,Gray E,Negrier C,Hemker HC,|standards,blood,drug effects,standards...

Guidelines for the management of hemophilia.
https://doi.org/10.1111/j.1365-2516.2012.02909.x
Haemophilia : the Official Journal of the World Federatio... Srivastava A, Brewer AK et. al.

Jul 11th, 2012 - Hemophilia is a rare disorder that is complex to diagnose and to manage. These evidence-based guidelines offer practical recommendations on the diagnosis and general management of hemophilia, as well as the management of complications including mu...

Preventing venous thromboembolic disease in patients undergoing elective hip and knee a...
https://doi.org/10.5435/00124635-201112000-00007
The Journal of the American Academy of Orthopaedic Surgeons; Mont MA, Jacobs JJ et. al.

Dec 3rd, 2011 - This guideline supersedes a prior one from 2007 on a similar topic. The work group evaluated the available literature concerning various aspects of patient screening, risk factor assessment, and prophylactic treatment against venous thromboembolic...

see more →

Drugs  110 results see all →

Clinicaltrials.gov  520 results

An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B
https://clinicaltrials.gov/ct2/show/NCT02554773

Aug 5th, 2022 - It is anticipated that patients in this study will receive treatment with open label fitusiran for approximately 7 years or until fitusiran becomes commercially available, whichever occurs first.

Posture Analysis for Patients With Haemophilia
https://clinicaltrials.gov/ct2/show/NCT05173129

Aug 5th, 2022 - Hemophilia A and B are inherited disorders characterized by deficient or missing coagulation factors VIII or IX, respectively, of which the main long-term clinical manifestation is joint damage. Patients with haemophilia (PwH) are susceptible to c...

Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor
https://clinicaltrials.gov/ct2/show/NCT05487976

Aug 4th, 2022 - Human coagulation factor VII is a vitamin K-dependent serine endogenous protease, and its activated form plays an important role in the coagulation process. Recombinant human activated coagulation factor VII is an activated state coagulation facto...

A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B
https://clinicaltrials.gov/ct2/show/NCT03861273

Aug 3rd, 2022 - This study will evaluate the efficacy and safety of PF-06838435 (a gene therapy drug) in adult male participants with moderately severe to severe hemophilia B (participants that have a Factor IX circulating activity of 2% or less). The gene therap...

HemLibra Prophylaxis in Patients With Hemophilic Pseudotumor
https://clinicaltrials.gov/ct2/show/NCT03921294

Aug 3rd, 2022 - This is a single arm, phase 4, prospective, open-label, United States single-center study to assess the hemostatic efficacy and safety of Hemlibra (emicizumab) for hemostatic control of hemophilia A patients, (baseline FVIII level <40%), children ...

see more →

News  676 results

Rituximab for Acquired Hemophilia A in the Setting of Bullous Pemphigoid
https://www.mdedge.com/dermatology/article/256573/mixed-topics/rituximab-acquired-hemophilia-setting-bullous-pemphigoid
Maria C. Bell, MD, Daniel C. Grove, MD et. al.

Jul 28th, 2022 - To the Editor: Bullous pemphigoid (BP) is an autoimmune blistering disease characterized by the formation of antihemidesmosomal antibodies, resulting in tense bullae concentrated on the extremities and trunk that often are preceded by a pruritic u.

No More Injections After One-Off Gene Therapy in Hemophilia B
https://www.medscape.com/viewarticle/977751

Jul 22nd, 2022 - UPDATED July 27, 2022 // Editor's note: This story has been updated with additional comments from Dr Pratima Chowdary, the lead author of the study. Patients with hemophilia B face a lifelong need for regular factor IX injections. But in 9 of 10 p...

Will the headache field embrace rofecoxib?
https://www.mdedge.com/neurology/article/256091/headache-migraine/will-headache-field-embrace-rofecoxib
Jennie Smith

Jul 7th, 2022 - In June, the Concord, Mass. –based company Tremeau Pharmaceuticals announced that the Food and Drug Administration was letting it proceed with a phase 3 clinical trial to test rofecoxib, the once-bestselling painkiller known as Vioxx, in patients w.

Will the Headache Field Embrace Rofecoxib (Vioxx)?
https://www.medscape.com/viewarticle/976762

Jul 7th, 2022 - In June, the Concord, Mass.–based company Tremeau Pharmaceuticals announced that the Food and Drug Administration was letting it proceed with a phase 3 clinical trial to test rofecoxib, the once-bestselling painkiller known as Vioxx, in patients w...

Debated: Nonfactor Versus Gene Therapy for Hemophilia
https://www.medscape.com/viewarticle/976107

Jun 23rd, 2022 - Whether hemophilia A patients should stick with effective nonfactor therapy or join a clinical trial for a potential cure with gene therapy – this question was debated at he annual meeting of the European Hematology Association. Ultimately, result...

see more →

Patient Education  11 results see all →